小方制药
(603207)
| 流通市值：11.71亿 | | | 总市值：47.01亿 |
| 流通股本：4000.00万 | | | 总股本：1.61亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 129,071,756.14 | 474,583,693.35 | 367,213,945.74 | 261,788,742.56 |
| 营业收入 | 129,071,756.14 | 474,583,693.35 | 367,213,945.74 | 261,788,742.56 |
| 二、营业总成本 | 59,389,758.13 | 236,453,654.47 | 179,224,454.99 | 122,116,783.78 |
| 营业成本 | 44,615,614.34 | 163,189,608.48 | 125,382,134.24 | 87,539,532.01 |
| 税金及附加 | 1,106,789.13 | 3,572,751.12 | 2,664,580.51 | 2,081,413.52 |
| 销售费用 | 8,913,240.57 | 41,581,084.29 | 30,176,932.37 | 20,471,502.44 |
| 管理费用 | 4,260,545.72 | 18,991,942.52 | 12,391,414.28 | 7,162,358 |
| 研发费用 | 2,270,871.64 | 15,105,418.01 | 10,672,621.35 | 6,561,697.12 |
| 财务费用 | -1,777,303.27 | -5,987,149.95 | -2,063,227.76 | -1,699,719.31 |
| 其中:利息费用 | - | 27,781.51 | 22,680.07 | 16,339.85 |
| 其中:利息收入 | -1,792,224.97 | -6,050,550.03 | -2,116,494.05 | -1,738,004.05 |
| 加:公允价值变动收益 | - | - | - | 15,584.9 |
| 加:投资收益 | - | 15,584.9 | 15,584.9 | - |
| 资产减值损失(新) | 122,667.07 | -90,259.85 | 49,200.85 | 37,154.74 |
| 信用减值损失(新) | -218,838.82 | -217,048.16 | -638,040.49 | -1,694,477.03 |
| 其他收益 | 356,137.49 | 1,978,671.81 | 1,665,052.33 | 1,213,222.86 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 69,941,963.75 | 239,816,987.58 | 189,081,288.34 | 139,243,444.25 |
| 减:营业外支出 | 100,000 | 310,077.11 | 310,077.11 | 310,054.1 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 69,841,963.75 | 239,506,910.47 | 188,771,211.23 | 138,933,390.15 |
| 减:所得税费用 | 9,999,301.58 | 34,235,814.97 | 27,101,723.92 | 20,117,459.32 |
| 六、净利润 | 59,842,662.17 | 205,271,095.5 | 161,669,487.31 | 118,815,930.83 |
| 持续经营净利润 | 59,842,662.17 | 205,271,095.5 | 161,669,487.31 | 118,815,930.83 |
| 归属于母公司股东的净利润 | 59,842,662.17 | 205,271,095.5 | 161,669,487.31 | 118,815,930.83 |
| (一)基本每股收益 | 0.37 | 1.53 | 1.28 | 0.99 |
| (二)稀释每股收益 | 0.37 | 1.53 | 1.28 | 0.99 |
| 九、综合收益总额 | 59,842,662.17 | 205,271,095.5 | 161,669,487.31 | 118,815,930.83 |
| 归属于母公司股东的综合收益总额 | 59,842,662.17 | 205,271,095.5 | 161,669,487.31 | 118,815,930.83 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-29 | 2024-08-07 |
| 审计意见(境内) | | 标准无保留意见 | | |